查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830613

腦瘤藥物市場（按產品類型、治療方法、腫瘤類型、最終用戶和分銷管道分類）—2025-2032 年全球預測

Brain Tumor Therapeutics Market by Product Type, Therapeutic Approach, Tumor Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年腦癌藥物市場規模將成長至 62.9 億美元，複合年成長率為 8.49%。

主要市場統計數據
基準年2024年 32.8億美元
預計2025年 35.6億美元
預測年份：2032年 62.9億美元
複合年成長率（%） 8.49%

為決策者提供現代腦腫瘤治療環境框架，整合臨床創新、照護途徑和商業化槓桿

腦腫瘤治療處於快速科學創新與持久臨床複雜性的交會點，需要高階主管能夠整合技術、臨床實務和商業策略。分子診斷和精準醫療的最新進展正在改變患者的治療路徑，拓展可用的干涉措施範圍，同時也提升了跨專業團隊協調治療的重要性。同時，影像和外科技術的創新正在改變手術全期決策，為設備和服務供應商創造新的機遇，使其能夠提升顯著的價值。

本報告的引言重點概括了影響原發性腦腫瘤治療方案的臨床、監管和商業性動態。它概述了常見的治療方法、輔助設備的作用，以及最終用戶（包括醫院、專科診所和門診手術中心）如何調整治療途徑。報告自始至終強調了循證應用的促進因素、報銷和可及性考量，以及對開發設備和藥物療法的公司的戰略意義。其目標是幫助決策者簡潔地了解問題陳述、商業化的關鍵槓桿，以及哪些領域的額外投資和合作可以帶來可衡量的臨床和經濟效益。

精準診斷、適應性證據產生和以價值為中心的護理模式如何重塑治療開發和商業性執行

腦腫瘤治療領域正在經歷變革性變化，這正在重新定義臨床決策和商業性重點。精準腫瘤學的進展，例如分子分型和標靶免疫治療，正在將異質性疾病類別轉化為更具可操作性的治療隊列，從而影響試驗設計、監管策略和市場准入順序。與藥理學進展同步，影像和放射治療技術也在不斷發展，從而提高了精準度並減輕了附帶損害，迫使臨床團隊重新思考治療順序和聯合策略。

同時，數位健康、真實世界證據和自適應臨床試驗框架的整合正在加速迭代學習，縮短從概念驗證到廣泛臨床應用的時間。支付者和醫療系統越來越關注基於價值的指標，要求製造商不僅要證明療效，還要證明長期患者療效和成本效益。因此，能夠將科學差異化與現實部署路徑（例如最佳化的分銷管道和醫院整合模式）相結合的公司將獲得巨大的臨床和商業性利益。這種轉變迫使製造商和供應商重新思考夥伴關係、證據產生和上市路徑，以保持競爭力。

評估近期關稅變化如何改變治療和醫療設備的供應鏈彈性、採購動態和商業性成本結構

貿易政策和關稅趨勢可能會為整個治療方法的製造商和經銷商帶來重大的成本和供應鏈考量。 2025年，美國關稅的變化對進口醫療設備和某些藥品投入產生了累積影響，促使製造商重新評估籌資策略和成本結構。對於器械製造商而言，依賴全球化供應鏈的組件（例如影像感測器和放射治療系統組件）的投入成本上漲，導致其重新評估與醫院系統和經銷商的採購談判。

當原料藥和特殊包裝從國際採購時，製藥商面臨間接成本壓力，這迫使他們重新談判契約，在某些情況下甚至需要部分回流或實現供應商多元化。這些調整強化了供應鏈透明度和與最終用戶簽訂合約彈性的重要性。醫療保健提供者和付款人對此的回應是要求提供更有力的醫療總成本證據，並延長保固期和服務承諾，以降低成本波動性。展望未來，積極將關稅相關成本納入定價、管理採購和臨床價值提案的相關人員將更有能力在保持利潤率的同時，保持淨利率的可及性和應用性。

分析醫療設備、藥品和臨床路徑的需求促進因素，以確定差異化的採用模式和商業化途徑

它確定了臨床需求和機會的交匯點，包括產品類型、治療方法、腫瘤類型、最終用戶和分銷管道。依產品類型，市場分為醫療設備和藥品。醫療設備包括診斷影像設備、放射設備和手術器械。化療包括烷化劑、抗代謝物和植物鹼。免疫療法包括CAR-T療法、查核點抑制劑和疫苗。放射線治療包括近距離放射治療、體外放射線治療和立體定位放射線手術。

不同類型的腫瘤（星狀細胞瘤、膠質母細胞瘤、腦膜瘤）表現出不同的臨床療效和治療強度，這會影響產品選擇和服務利用。最終用戶（例如門診手術中心、醫院和專科診所）擁有不同的資本預算、病例組合和轉診網路，這些因素決定了採購時間表和商業性參與策略。分銷管道（例如醫院藥房、線上藥房和零售藥房）影響患者的用藥管道、依從性支援和管道經濟效益。綜上所述，這些細分市場表明，根據特定的產品、治療方法、腫瘤類型和醫療環境組合，量身定做臨床證據、定價模型和上市後服務，對於加速藥物應用和確立商業性定位至關重要。

發現區域監管和付款人的異質性，以協調證據生成、市場進入順序和區域商業化策略，實現全球擴張

區域動態決定了不同的監管、報銷和臨床應用環境，因此需要製定針對特定區域的市場策略。在美洲，領先的學術中心和綜合醫療系統通常會推動高成本療法和複雜醫療設備的早期採用，而私人付款人和捆綁支付模式則決定了醫療服務的取得和報銷途徑。在歐洲、中東和非洲，監管的多樣性和不同的報銷門檻，再加上集中核准和分散的衛生技術評估並存，需要靈活的證據基礎和針對特定區域的經濟模式。亞太地區在醫療保健現代化方面呈現不同的軌跡。在某些市場，醫院的快速擴張和對腫瘤中心的投資正在創造對高性能醫療設備和新型療法的巨大需求，而在其他市場，則強調成本控制和本地製造合作夥伴關係。

這些區域差異會影響臨床試驗地點的選擇、市場進入時機以及患者可近性計畫的設計。因此，製造商必須調整其監管策略、本地證據產生和經銷夥伴關係，以符合區域付款人的期望和供應商的能力。此外，與關鍵意見領袖和區域臨床網路的合作對於將全球證據轉化為本地相關的實踐變革並加快本地報銷談判至關重要。

創新者、設備製造商和經銷商的產品和服務整合策略如何重新定義競爭優勢和夥伴關係模式

腦腫瘤治療生態系統的關鍵參與者在互補領域開展業務，包括創新藥物開發商、設備製造商、服務供應商和專業分銷商，各自構成複雜的價值鏈。製藥創新者擴大將分子標靶療法和免疫療法與伴隨診斷相結合，從而增強了生物標記主導的患者選擇在臨床和商業性成功中的作用。醫療設備製造商正在透過結合成像、導航和治療交付的整合解決方案實現差異化，以簡化手術工作流程並改善臨床結果。

服務供應商和委外研發機構正在擴展其服務範圍，以支援自適應試驗設計、真實世界證據平台和健康經濟模型，使申辦方能夠更快地證明其價值提案。分銷商和專業藥房正在加強患者援助計劃和專業物流，以滿足重症患者的需求。在整個生態系統中，共同開發、授權或綜合服務協議等策略聯盟正成為降低創新風險、加速臨床試驗和上市時間的首選方式。能夠展示綜合解決方案、可擴展支持模式和強大臨床證據的組織將在臨床應用和長期商業性永續性方面處於領先地位。

高階主管應優先採取的策略性措施是同步證據產生、供應彈性和靈活的商業化，以加速採用

行業領導者應優先考慮一系列切實可行的舉措，將科學差異化與現實的商業性執行和付款人期望相結合。首先，投資於有針對性的證據生成，將臨床終點與健康經濟結果相結合，使付款人和醫療系統能夠評估長期價值和短期有效性。其次，透過多元化採購、確保關鍵零件的冗餘性以及將關稅和貿易敏感性分析納入定價模型來最佳化供應鏈彈性，以保護利潤率和醫療服務的連續性。第三，發展靈活的商業模式，以反映最終用戶的多樣性。醫院、門診手術中心和專科診所各自需要不同的收購、資金籌措和服務結構。

此外，儘早與當地監管和報銷相關人員溝通，確保滿足當地證據要求，並考慮採用適應性試驗設計和實用性研究，以加速現實世界的推廣應用。建立策略聯盟，將設備和療法與數位工具和病患支援服務結合，打造捆綁式價值提案。最後，優先進行臨床醫師和病患教育項目，以闡明治療順序、聯合治療原理和預期療效，從而鋪平從監管核准到納入標準治療的整個過程。這些行動結合起來，可以減少推廣障礙，增強商業性韌性。

將臨床、商業和政策情報與專家訪談和比較案例分析相結合的透明混合方法可確保獲得切實可行的見解

本分析所依據的調查方法穩健有效，透過系統性文獻綜述、與領域專家進行初步定性訪談以及對二手資料來源的三角檢驗，得以驗證。初步訪談對象包括臨床醫生、醫院採購負責人、設備工程師、付款方和商務主管，旨在了解跨職能觀點對臨床效用、採購偏好和市場進入條件的看法。二級資訊來源包括同儕審查的臨床文獻、監管備案文件、指南更新和公共公告，旨在為檢驗證據和當前實踐模式提供深入見解。

資料整合利用主題分析來識別反覆出現的採用促進因素、障礙和區域差異，而比較案例研究突顯了商業化成功案例和夥伴關係關係典範。在適當的情況下，我們進行了敏感性檢驗，以檢驗關於供應鏈動態和醫療保健提供者購買行為的假設。本調查方法強調資訊來源歸因和分析假設的透明度，旨在為策略規劃、夥伴關係評估和證據產生優先排序提供可靠且可操作的見解。

整合臨床創新、商業性嚴謹性和本地細微差別，以確定將治療進步轉化為持久影響的策略槓桿

總而言之，腦腫瘤治療領域的特點是科學進步迅速、治療途徑不斷發展以及商業性動態複雜，需要涵蓋證據生成、供應鏈設計和市場准入的整合策略。精準診斷和新型免疫療法正在提高臨床差異化的標準，而影像、放射和外科技術的進步正在重塑實踐模式。同時，關稅和貿易變化暴露了供應鏈的脆弱性，需要積極主動的管理來維持可及性和財務績效。監管和報銷方面的區域差異進一步凸顯了製定本地策略和夥伴關係關係的必要性。

綜上所述，能夠將可靠的臨床證據與實用的商業模式、靈活的採購慣例以及有針對性的本地參與相結合的組織，將最有能力將創新轉化為持續的臨床和商業性影響力。未來的道路是強調產業、相關人員和付款相關人員之間的合作，以及嚴謹的證據和價值展示方法，以滿足醫療服務提供者和病患的需求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對腫瘤特異性抗原的個人化疫苗療法的應用日益廣泛
  • 免疫療法與標靶藥物結合的多模態治療方法的出現
  • 基於血液的液態生物檢體檢測在早期檢測腦腫瘤復發的進展
  • 增加對侵襲性和復發性膠質母細胞瘤 CAR-T 細胞療法的投資
  • 整合人工智慧影像分析，改善腫瘤分割和治療計劃
  • 治療瀰漫性內源性腦橋膠質瘤的血腦障壁滲透性小分子化合物的開發
  • 患者報告的結果對於指導神經認知保留治療策略的重要性日益增加
  • 生物技術先驅與學術機構進行策略合作，共同發現新的膠質瘤標靶
  • 監管部門的核准加速了高級別膠質瘤溶瘤病毒療法的普及
  • 投資自適應臨床試驗設計加速腦腫瘤治療評估

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章腦瘤藥物市場（依產品類型）

  • 裝置
    • 影像設備
    • 輻射設備
    • 手術器械
  • 製藥

第9章腦腫瘤藥物市場（依治療方法）

  • 化療
    • 烷化劑
    • 抗代謝物
    • 植物生物鹼
  • 免疫療法
    • CAR T
    • 查核點抑制劑
    • 疫苗
  • 放射線治療
    • 近距離放射治療
    • 體外放射治療
    • 立體定位放射線手術
  • 外科手術
    • 開顱手術
    • 立體定位手術

第 10 章腦腫瘤藥物市場（依腫瘤類型）

  • 星狀細胞瘤
  • 神經膠母細胞瘤
  • 腦膜瘤

第 11 章腦腫瘤藥物市場（依最終使用者）

  • 門診手術中心
  • 醫院
  • 專科診所

第12章腦腫瘤藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章腦瘤藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章腦腫瘤藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦瘤藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novocure Ltd.
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • AbbVie Inc.
    • AstraZeneca plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
Product Code: MRR-4342CA326550

The Brain Tumor Therapeutics Market is projected to grow by USD 6.29 billion at a CAGR of 8.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.28 billion
Estimated Year [2025] USD 3.56 billion
Forecast Year [2032] USD 6.29 billion
CAGR (%) 8.49%

Framing the contemporary brain tumor therapeutic environment by integrating clinical innovation, care pathways, and commercialization levers for decision-makers

Brain tumor therapeutics sit at the intersection of rapid scientific innovation and enduring clinical complexity, requiring an executive lens that integrates technology, clinical practice, and commercial strategy. Recent advances in molecular diagnostics and precision therapeutics have altered patient pathways, expanding the range of interventions available while also increasing the importance of coordinated care across multidisciplinary teams. At the same time, procedural innovations in imaging and surgical techniques have changed perioperative decision making, creating new opportunities for device and service providers to add demonstrable value.

This introduction positions the report as a focused synthesis of clinical, regulatory, and commercial dynamics shaping therapeutic choices for primary brain tumors. It outlines the prevailing therapeutic approaches, the role of complementary devices, and how end users such as hospitals, specialty clinics, and ambulatory surgical centers are adapting care pathways. Throughout, emphasis is placed on evidence-based adoption drivers, reimbursement and access considerations, and the strategic implications for companies developing devices or pharmacologic therapies. The aim is to equip decision-makers with a concise framing of the problem set, the levers that matter in commercialization, and the domains where additional investment or collaboration can yield measurable clinical and economic returns.

How precision diagnostics, adaptive evidence generation, and value-focused care models are reshaping therapeutic development and commercial execution

The landscape for brain tumor therapeutics is undergoing transformative shifts that are redefining clinical decision-making and commercial priorities. Precision oncology advances, such as molecular subtyping and targeted immunotherapies, have converted heterogeneous disease categories into more actionable treatment cohorts, thereby influencing trial design, regulatory strategy, and market entry sequencing. Parallel to pharmacologic progress, imaging and radiation technologies have evolved to provide greater precision and reduced collateral damage, prompting clinical teams to reassess treatment sequencing and combination strategies.

Concurrently, the convergence of digital health, real-world evidence, and adaptive clinical trial frameworks has accelerated iterative learning, shortening the time between proof-of-concept and broader clinical adoption. Payers and health systems are increasingly focused on value-based metrics, pushing manufacturers to demonstrate not only efficacy but also longitudinal patient outcomes and cost-effectiveness. As a result, organizations that can align scientific differentiation with pragmatic deployment pathways-such as optimized distribution channels and hospital integration models-will capture disproportionate clinical and commercial upside. These shifts compel manufacturers and providers to rethink partnerships, evidence generation, and market access pathways in order to remain competitive.

Assessing how recent tariff developments have altered supply chain resilience, procurement dynamics, and commercial cost structures in therapeutics and devices

Trade policy and tariff dynamics can introduce material cost and supply chain considerations for manufacturers and distributors across therapeutic modalities. In 2025, tariff changes in the United States have had a cumulative effect on imported devices and certain pharmaceutical inputs, prompting manufacturers to reassess sourcing strategies and cost structures. For device makers, components that rely on globalized supply chains, including imaging sensors or radiation delivery system parts, experienced input-cost inflation that translated to revised procurement discussions with hospital systems and distributors.

Pharmaceutical manufacturers faced indirect cost pressure where APIs and specialty packaging were sourced internationally, requiring contract renegotiations and, in some instances, partial reshoring or diversification of suppliers. These adjustments increase the importance of supply chain transparency and contractual flexibility with end users. Providers and payers responded by seeking stronger total-cost-of-care evidence and longer-term warranties or service commitments to mitigate variability. Moving forward, stakeholders that proactively model tariff-related expenses into pricing, managed procurement, and clinical value propositions will be better positioned to sustain margins while preserving access and adoption.

Dissecting demand drivers across devices versus pharmaceuticals and clinical pathways to reveal differentiated adoption patterns and commercialization levers

Key segmentation insights reveal where clinical demand and commercial opportunity intersect across product type, therapeutic approach, tumor type, end user, and distribution channels. When analyzed by product type, the market divides into devices and pharmaceutical offerings, with devices themselves comprising imaging equipment, radiation equipment, and surgical instruments; this division highlights different adoption cycles, capital expenditure profiles, and service model requirements for providers. Therapeutic approach further stratifies demand across chemotherapy, immunotherapy, radiotherapy, and surgery; chemotherapy includes alkylating agents, antimetabolites, and plant alkaloids, while immunotherapy encompasses CAR T therapies, checkpoint inhibitors, and vaccines, and radiotherapy spans brachytherapy, external beam radiotherapy, and stereotactic radiosurgery, whereas surgical approaches range from craniotomy to stereotactic surgery, each pathway implicating distinct clinical workflows and evidence needs.

Tumor type segmentation-astrocytoma, glioblastoma, and meningioma-illustrates heterogeneous clinical outcomes and treatment intensity, which in turn affect product selection and service utilization. End users such as ambulatory surgical centers, hospitals, and specialty clinics differ in their capital budgets, case-mix, and referral networks, shaping procurement timelines and commercial engagement strategies. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies influence patient access, adherence support, and channel economics. Taken together, these segmentations underline that tailoring clinical evidence, pricing models, and post-market services to the specific combination of product, therapy, tumor type, and care setting is essential to accelerate adoption and create defensible commercial positioning.

Unpacking regional regulatory and payer heterogeneity to tailor evidence generation, market entry sequencing, and local commercialization tactics for global reach

Regional dynamics create distinct regulatory, reimbursement, and clinical adoption environments that require localized go-to-market strategies. In the Americas, advanced academic centers and integrated health systems often drive early adoption of high-cost therapeutics and complex devices, while private payers and bundled payment models shape access and reimbursement pathways. Europe, the Middle East & Africa encompasses regulatory heterogeneity and varying reimbursement thresholds, where centralized approvals coexist with decentralized health technology assessments, necessitating flexible evidence dossiers and region-specific economic models. Asia-Pacific presents diverse healthcare modernization trajectories; in some markets rapid hospital expansion and investment in oncology centers create significant demand for high-capability devices and novel therapeutics, whereas other markets emphasize cost containment and local manufacturing partnerships.

These regional contrasts affect clinical trial site selection, timing of market entry, and the design of patient access programs. Manufacturers must therefore calibrate regulatory strategies, local evidence generation, and distribution partnerships to align with regional payer expectations and provider capabilities. Moreover, engagement with key opinion leaders and local clinical networks is essential to translate global evidence into locally relevant practice change and to expedite reimbursement discussions in each jurisdiction.

How integrated product and service strategies among innovators, device makers, and distributors are redefining competitive advantage and partnership models

Key companies in the brain tumor therapeutics ecosystem operate across complementary domains-innovative drug developers, device manufacturers, service providers, and specialized distributors-each contributing to a complex value chain. Pharmaceutical innovators are increasingly pairing molecularly targeted agents and immunotherapies with companion diagnostics, elevating the role of biomarker-driven patient selection in clinical and commercial success. Device manufacturers are differentiating through integrated solutions that combine imaging, navigation, and therapeutic delivery to streamline operative workflows and improve clinical outcomes.

Service providers and contract research organizations are expanding offerings to support adaptive trial designs, real-world evidence platforms, and health economic modeling, enabling sponsors to substantiate value propositions more rapidly. Distributors and specialty pharmacies are enhancing patient support programs and specialty logistics to address the needs of high-acuity populations. Across the ecosystem, strategic collaborations-whether co-development, licensing, or integrated service agreements-have become a preferred vehicle to de-risk innovation and accelerate time-to-clinic or time-to-market. Organizations that can demonstrate integrated solutions, scalable support models, and strong clinical evidence will lead in both clinical adoption and long-term commercial sustainability.

Prioritized strategic moves for executives to synchronize evidence generation, supply resilience, and flexible commercialization to accelerate adoption

Industry leaders should prioritize a set of actionable initiatives that align scientific differentiation with pragmatic commercial execution and payer expectations. First, invest in targeted evidence generation that pairs clinical endpoints with health economic outcomes, enabling payers and health systems to assess long-term value alongside short-term efficacy. Second, optimize supply chain resilience by diversifying sourcing, building redundancy for critical components, and embedding tariff and trade sensitivity analyses into pricing models to protect margins and continuity of care. Third, develop flexible commercial models that reflect end-user variability; hospitals, ambulatory surgical centers, and specialty clinics require different acquisition, financing, and service arrangements.

Additionally, engage early with regional regulatory and reimbursement stakeholders to ensure local evidence requirements are met, and consider adaptive trial designs or pragmatic studies to accelerate real-world adoption. Form strategic alliances that integrate devices and therapeutics with digital tools and patient support services to create bundled value propositions. Finally, prioritize clinician and patient education programs that clarify treatment sequencing, combination therapy rationale, and outcome expectations, thereby smoothing the pathway from regulatory approval to standard-of-care integration. Collectively, these actions will reduce barriers to adoption and enhance commercial resilience.

A transparent mixed-methods approach combining clinical, commercial, and policy intelligence with expert interviews and comparative case analyses to ensure actionable insights

The research methodology underpinning this analysis combines systematic literature review, primary qualitative interviews with subject matter experts, and triangulation of secondary data sources to ensure robustness and relevance. Primary interviews included clinicians, hospital procurement leaders, device engineers, payers, and commercial executives to capture cross-functional perspectives on clinical utility, procurement preferences, and market access contingencies. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, guideline updates, and public policy announcements to ground the findings in verifiable evidence and current practice patterns.

Data synthesis employed thematic analysis to identify recurring adoption drivers, barriers, and regional variances, while comparative case studies highlighted successful commercialization and partnership archetypes. Where appropriate, sensitivity checks were performed to validate assumptions around supply chain dynamics and provider purchasing behaviors. The methodology emphasizes transparency in source attribution and analytical assumptions and was designed to produce actionable insights that are reliable for strategic planning, partnership evaluation, and evidence generation prioritization.

Synthesizing clinical innovation, commercial rigor, and regional nuance to identify the strategic levers that convert therapeutic advances into durable impact

In conclusion, the brain tumor therapeutics arena is characterized by rapid scientific progress, evolving care pathways, and complex commercial dynamics that together demand integrated strategies across evidence generation, supply chain design, and market access. Precision diagnostics and novel immunotherapies have raised the bar for clinical differentiation, while advances in imaging, radiation delivery, and surgical technique are reshaping practice patterns. At the same time, tariff and trade shifts have exposed supply chain vulnerabilities that require proactive management to preserve access and fiscal performance. Regional heterogeneity in regulation and reimbursement further underscores the need for localized strategies and partnerships.

Taken together, organizations that can align robust clinical evidence with pragmatic commercial models, resilient procurement practices, and targeted regional engagement will be best positioned to convert innovation into sustained clinical and commercial impact. The path forward emphasizes collaboration across industry, clinical, and payer stakeholders, and a disciplined approach to evidence and value demonstration that meets the needs of providers and patients alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of personalized vaccine therapies targeting tumor-specific antigens
  • 5.2. Emergence of multi-modal treatment regimens combining immunotherapy and targeted agents
  • 5.3. Advancements in blood-based liquid biopsy assays for early detection of brain tumor recurrence
  • 5.4. Rising investment in CAR T-cell therapies for aggressive and recurrent glioblastoma cases
  • 5.5. Integration of AI-powered imaging analytics to improve tumor segmentation and treatment planning
  • 5.6. Development of blood-brain barrier penetrating small molecules for diffuse intrinsic pontine glioma
  • 5.7. Growing emphasis on patient-reported outcomes to guide neurocognitive sparing treatment strategies
  • 5.8. Strategic collaborations between biotech pioneers and academic centers for novel glioma target discovery
  • 5.9. Regulatory approvals accelerating availability of oncolytic virus therapies for high-grade gliomas
  • 5.10. Investment in adaptive clinical trial designs to accelerate brain tumor therapeutic evaluations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Therapeutics Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Equipment
    • 8.1.2. Radiation Equipment
    • 8.1.3. Surgical Instruments
  • 8.2. Pharmaceutical

9. Brain Tumor Therapeutics Market, by Therapeutic Approach

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. CAR T
    • 9.2.2. Checkpoint Inhibitors
    • 9.2.3. Vaccines
  • 9.3. Radiotherapy
    • 9.3.1. Brachytherapy
    • 9.3.2. External Beam Radiotherapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Surgery
    • 9.4.1. Craniotomy
    • 9.4.2. Stereotactic Surgery

10. Brain Tumor Therapeutics Market, by Tumor Type

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma
  • 10.3. Meningioma

11. Brain Tumor Therapeutics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Brain Tumor Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Brain Tumor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Tumor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Tumor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. F. Hoffmann-La Roche Ltd.
    • 16.3.3. Novocure Ltd.
    • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.5. Pfizer Inc.
    • 16.3.6. AbbVie Inc.
    • 16.3.7. AstraZeneca plc
    • 16.3.8. Novartis AG
    • 16.3.9. Teva Pharmaceutical Industries Ltd.
    • 16.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018